VS 014
Alternative Names: VS-014Latest Information Update: 29 Feb 2024
At a glance
- Originator Biomedical Advanced Research and Development Authority; University of Florida Research Foundation
- Developer Nuvara Therapeutics
- Class Amino acids; Antidiarrhoeals
- Mechanism of Action Chloride channel modulators; Cystic fibrosis transmembrane conductance regulator modulators; Sodium-hydrogen antiporter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diarrhoea
Most Recent Events
- 29 Feb 2024 Nuvara Therapeutics intends to submit IND application for phase II clinical trial for Diarrhoea in 2024 (Nuvara Therapeutics pipeline, February 2024)
- 14 Dec 2021 Preclinical trials in Diarrhoea in USA (Enteral) prior to December 2021 (Nuvara Therapeutics pipeline, December 2021)
- 14 Dec 2021 Nuvara Therapeutics plans phase I trial for Diarrhoea in USA in 2022 (Nuvara Therapeutics pipeline, December 2021)